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A B S T R A C T
Background
People living with end-stage kidney disease (ESKD) often develop anaemia. Erythropoiesis-simulating agents (ESAs) are often given to
people living with ESKD to maintain haemoglobin at a level to minimise need for transfusion. However, about 5% to 10% of patients
with ESKD exhibit resistance to ESAs, and observational studies have shown that patients requiring high doses of ESA are at increased
risk of mortality.
Objectives
This review aimed to study the effects of interventions for the treatment of ESA-resistant anaemia in people with ESKD.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE for randomised controlled
trials (RCT) that involved participants with ESKD on dialysis or who were pre-dialysis patients with chronic kidney disease (stage 5).
Date of last search: April 2013.
Selection criteria
ESA resistance was defined as failure to achieve or maintain haemoglobin/haematocrit levels within the desired target range despite
appropriate ESA doses (erythropoietin ≥ 450 U/kg/wk intravenously or ≥ 300 U/kg/wk subcutaneously; darbepoetin ≥ 1.5 µg/kg/
wk) in people who were not nutritionally deficient, or who had haematological or bleeding disorders. Extended inclusion criteria for
ESA hyporesponsive state were: erythropoietin dose ≥ 300 U/kg/wk and ≥ 150 U/kg/wk for intravenous administration; or ≥ 200 U/
kg/wk and ≥ 100 U/kg/wk for subcutaneous administration; or darbepoetin dose ≥ 1.0 µg/kg/wk).
Data collection and analysis
Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random effects model
and results expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).
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Main results
Titles and abstracts of 521 records were screened, of which we reviewed 99 from the full text. Only two studies matched our inclusion
criteria. One study compared intravenous vitamin C versus no study medication for six months in 42 ESKD patients on haemodialysis
who required intravenous erythropoietin (dose ≥ 450 U/kg/wk). The other included study compared high-flux dialyser versus low-
flux dialyser for six months in 48 haemodialysis patients who required subcutaneous erythropoietin (dose ≥ 200 U/kg/wk). Because
interventions differed, data could not be combined for quantitative meta-analysis.
Authors’ conclusions
There was inadequate evidence identified to inform recommendation of any intervention to ameliorate ESA hyporesponsiveness.
Adequately powered RCTs are required to establish the safety and efficacy of interventions to improve responsiveness to ESA therapy.
P L A I N L A N G U A G E S U M M A R Y
Interventions for anaemia in dialysis patients who are resistant to erythropoietin
Many people with chronic kidney disease (CKD) who are on dialysis develop anaemia (too few or poor quality red blood cells). Drugs
in the erythropoiesis-stimulating family increase the production of red blood cells to resolve anaemia. Although ESAs have been highly
beneficial for many, about 10% of people get either low or no benefit from treatment. Inability to control and stabilise anaemia can
lead to poor rates of survival and increased risk of stroke so it is important to find effective treatment to manage anaemia in people who
do not respond adequately to ESA therapy.
We searched the literature to find evidence about how best to treat people who do not benefit from ESA treatment. We found two
studies: one that assessed intravenous vitamin C and another that looked at high-flux dialyser fluids as possible therapies. These studies
were small (total of 90 participants) and were selective: they included haemodialysis, but not peritoneal dialysis, patients. This meant
that the results of these studies could not be applied to all people with CKD on dialysis who were receiving ESA therapy. The lack of
evidence meant that we could not determine or recommend an alternate treatment for people who do not respond to ESA.
More powerful and rigorous studies are needed to systematically assess all therapies that are aimed to treat people who do not respond
to ESA therapy. Until such evidence is available, no therapy can be confidently recommended for this problem.
B A C K G R O U N D
Description of the condition
Erythropoiesis-stimulating agents (ESAs) are perhaps the most
rigorously tested group of drugs in nephrology. Since the intro-
duction of ESAs, there have been substantial reductions in blood
transfusion requirements among patients living with chronic kid-
ney disease (CKD) (Eschbach 1989).
A systematic review of 14 randomised controlled and uncontrolled
trials in pre-dialysis CKD patients demonstrated that treatment of
anaemia with ESAs improved energy levels and physical function
(Gandra 2010). Unfortunately, a considerable proportion of these
patients exhibited suboptimal haematologic response to ESA (
Benz 1999; Valderrabano 1996).
There are several known causes of suboptimal response to ESA.
These include deficiencies in iron, vitamin B12, and folate; infec-
tion, chronic inflammatory state, neoplasia, severe hyperparathy-
roidism, aluminium intoxication, inadequate dialysis, myelosup-
pressive agents, haemoglobinopathies, myelodysplasia and anti-
body-mediated pure red cell aplasia (Macdougall 2002). How-
ever, after excluding these conditions it was found that about 10%
of patients exhibit ESA-resistant anaemia, and these people have
greatly increased rates of morbidity and mortality (Kausz 2005;
Macdougall 2002; Zhang 2004).
ESA treatment used to target high haemoglobin levels in people
with CKD is associated with deleterious (Phrommintikul 2007)
or neutral (Palmer 2010) impacts on survival and increased risks of
stroke, vascular access thrombosis and hypertension without any
reduction in cardiovascular events (Palmer 2010; Phrommintikul
2007).
2Interventions for erythropoietin-resistant anaemia in dialysis patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Although RCTs and systematic reviews consistently show more
harm than benefit associated with higher haemoglobin targets
for ESA treatment (Besarab 1998; Palmer 2010; Pfeffer 2009;
Phrommintikul 2007; Singh 2006), secondary analyses of RCTs
and observational studies have demonstrated that poor response
to ESA treatment rather than achieved high haemoglobin, may be
responsible for the observed suboptimal outcomes in people with
CKD (Kilpatrick 2008; Messana 2009; Regidor 2006; Solomon
2010; Szczech 2008).
These studies also showed that patients who required higher doses
of ESA experienced increased mortality at any haemoglobin level,
and that patients who achieve target haemoglobin levels had bet-
ter outcomes than those who did not (Badve 2011). Therefore,
therapies targeting ESA resistance could be a promising treatment
strategy in CKD anaemia management.
Description of the intervention
Although there is no effective treatment for patients with ESA-
resistant anaemia at present, a number of interventions such as L-
carnitine, ascorbic acid, oxpentifylline, androgens and statins have
been investigated.
O B J E C T I V E S
This review looked at the benefits and harms of any intervention
used in the treatment of ESA-resistant anaemia in people with
end-stage kidney disease (ESKD) who were receiving dialysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (stud-
ies in which allocation to treatment was obtained by alternation,
use of alternate medical records, date of birth or other predictable
methods) looking at interventions for the treatment of ESA-resis-
tant anaemia in people with ESKD were included in our review.
Types of participants
• Adults and children with ESKD (chronic kidney disease
(CKD) stage 5 or pre-dialysis) or those receiving dialysis (either
haemodialysis or peritoneal dialysis).
• Adults and children with ESKD receiving any type of ESA
for anaemia (anaemia defined as haemoglobin < 110 g/L or as
defined by the investigators).
• Evidence of ESA resistance, defined as failure to achieve or
maintain target range haemoglobin/haematocrit levels in spite of
appropriate ESA doses (erythropoietin ≥ 450 U/kg/wk
intravenous administration or ≥ 300 U/kg/wk for subcutaneous
administration or darbepoetin ≥ 1.5 µg/kg/wk) (KDOQI 2001;
Locatelli 2004). This inclusion criterion was amended after
publication of the protocol of this systematic review because only
one eligible study was found. Extended inclusion criteria were
studies that defined ESA-hyporesponsive state as failure to
achieve or maintain target haemoglobin/haematocrit in spite of
the following doses of the ESA: erythropoietin dosage ≥ 300 and
≥150 U/kg/wk for IV administration; or ≥ 200 and ≥100 U/
kg/wk for subcutaneous administration; or darbepoetin dosage
≥ 1.0 µg/kg/wk).
• All known causes of ESA-resistance (such as iron deficiency,
vitamin B12 deficiency, folate deficiency, infection, chronic
inflammatory state, neoplasia, severe hyperparathyroidism,
aluminium intoxication, inadequate dialysis, myelosuppressive
agents, haemoglobinopathies, myelodysplasia and antibody-
mediated pure red cell aplasia) must have been ruled out.
• Studies performed in kidney transplant recipients were
excluded.
Types of interventions
Any potential intervention used to treat ESA-resistance, such as
L-carnitine, ascorbic acid, oxpentifylline, androgens, and statins,
were included in this review.
Types of outcome measures
• All-cause mortality
• Cardiovascular mortality
• Non-fatal cardiovascular events
• Number of patients achieving target haemoglobin/
haematocrit
• Difference or changes in haemoglobin or haematocrit
between intervention and control groups at study end
• Difference or changes in ESA dose between intervention
and control groups at study end
• Blood transfusion requirements
• Quality of life
• Hospitalisation
• Any reported adverse events
• Differences or changes in inflammatory biomarkers
between intervention and control groups at study end
• Differences or changes in biomarkers of oxidative stress
between intervention and control groups at study end.
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Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group’s specialised register 18th
March 2013 through contact with the Trials’ Search Co-ordinator
using search terms relevant to this review.
The Cochrane Renal Group’s Specialised Register contains studies
identified from:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the specialised register are identified through
search strategies for CENTRAL, MEDLINE and EMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts, are available in the specialised
register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies.
2. Relevant missing or incomplete or unpublished data from
the clinical studies were requested from the respective
investigators/ authors by written correspondence.
Data collection and analysis
Selection of studies
The search strategy describedwas used to obtain titles and abstracts
of studies relevant to the review. Titles and abstracts were screened
independently by three authors, who discarded studies that were
not applicable. However, studies and reviews that potentially in-
cluded relevant data or study information were retained initially.
The same three authors independently assessed retrieved abstracts,
and if necessary the full text, of these studies to determine which
studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals was to be translated before assessment.
Where more than one publication of one study existed, reports
were grouped together and the publication with the most com-
plete data was used in the analyses. Where relevant outcomes were
only published in earlier versions, these data were used. Any dis-
crepancies between published versions was to be highlighted. Dis-
agreements were resolved by consensus.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (all-cause mortality, cardiovascular
mortality, non-fatal cardiovascular events, number of patients
achieving haemoglobin/haematocrit targets, number of patients
requiring hospitalisation, number of patients requiring blood
transfusions, number of patients with medication-related adverse
effects), results were expressed as risk ratios (RR) with 95% confi-
dence intervals (CI). For continuous data (haemoglobin, haemat-
ocrit, iron studies, ESA dosage, iron dosage, hospitalisation days,
quality of life scores, inflammatory biomarkers, biomarkers of ox-
idative stress), results were expressed as mean difference (MD).
Dealing with missing data
We planned that any further information required from the origi-
nal author was to be requested by written correspondence, and any
relevant information obtained was be included in the review. Eval-
uation of important numerical data such as screened, randomised
patients as well as intention-to-treat (ITT), as-treated and per-
protocol (PP) population was performed.
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Assessment of heterogeneity
Heterogeneity was to be analysed using a Chi² test on N-1 degrees
of freedom, with an alpha of 0.05 used for statistical significance
and with the I² test (Higgins 2003). I² values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity.
Data synthesis
Data were to be pooled using the random-effects model.
R E S U L T S
Description of studies
Results of the search
We identified 533 abstracts using the search strategy described
(Figure 1). After screening titles and abstracts, 99 reports were
selected for full text review. Only two studies (Attallah 2006; Ayli
2004) met our inclusion criteria, and of these, one investigated
our extended inclusion criterion of ESA hyporesponsive state (Ayli
2004).
Figure 1. The PRISMA flow chart showing selection of studies
We considered inclusion of a study that applied our extended
inclusion criterion of ESA-hyporesponsive state (Sezer 2002). In
this study, participants in both arms received the investigational
drug (vitamin C) in the first study phase (eight weeks). Non-
responders were excluded at the end of the first phase. During the
second phase, remaining participants were randomised to receive
either the investigational drug at a reduced frequency or no study
drug for another eight weeks. Since the investigators did not define
’non-responder’, and there was a strong possibility of carry over
effect of vitamin C administered before randomisation, the study
was excluded from this systematic review.
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Included studies
Two studies met our inclusion criteria.
• Attallah 2006 enrolled 42 haemodialysis patients and
compared IV vitamin C given at each dialysis session to no
treatment.
• Ayli 2004 enrolled 48 haemodialysis patients and compared
high-flux versus low-flux dialysis membranes
Excluded studies
We excluded 68 studies after full-text review: six were not ran-
domised; 58 included participants who did not have ESA resis-
tance; two included iron deficient participants who lacked true
ESA resistance; and two studies did not use ESA in the control
arm.
Risk of bias in included studies
Allocation
Allocation concealment was unclear in both included studies (
Attallah 2006; Ayli 2004).
Blinding
It was unclear if in Attallah 2006, an open-label study, outcome
assessors were blinded. Likewise, blinding of participants, investi-
gators or outcome assessors in Ayli 2004 was also unclear.
Incomplete outcome data
All participants were followed for the entire study period and ac-
counted for in both studies. Attrition bias arising from incomplete
outcome reporting was deemed to be low risk.
Selective reporting
Neither study reported proportions of participants in each study
armwho achieved haemoglobin target levels. The risk of reporting
bias in both was therefore unclear.
Other potential sources of bias
Both studies were judged to be at high risk of other potential
sources of bias due to single-centre study design and exclusion of
patients on peritoneal dialysis.
Effects of interventions
Treatments differed in the interventional arms of Attallah 2006
and Ayli 2004 (vitamin C and high-flux dialyser). Therefore, data
were not combined and results are presented separately.
Clinical outcomes
All-cause and cardiovascular mortality
No deaths were reported in either study.
Non-fatal cardiovascular events
Attallah 2006 reported no significant difference in the risk of non-
fatal cardiovascular events between study arms (Analysis 1.1: RR
0.79, 95% CI 0.20 to 3.09).
Ayli 2004 did not report non-fatal cardiovascular events.
Participants achieving target haemoglobin or haematocrit
Neither study reported the proportions of participants who
achieved target haemoglobin or haematocrit levels.
Requirement of blood transfusions
Attallah 2006 reported no participants included in the final analy-
sis required blood transfusion. However, one participant from the
control group was excluded from the final analysis because of the
need for a blood transfusion due to a significant upper gastroin-
testinal bleed.
Ayli 2004 did not report need for blood transfusion.
Hospitalisations
Attallah 2006 reported no significant difference in the risk of hos-
pitalisations between the groups (Analysis 1.2: RR 0.96, 95% CI
0.56 to 1.66).
Ayli 2004 did not report hospitalisations.
Medication-related adverse events
Attallah 2006 reported there were no adverse events noted in either
group. Ayli 2004 did not report adverse events.
Haematology and biochemistry results
Haemoglobin
Both studies reported significantly higher haemoglobin levels in
the treatment groups compared to the control groups (Analysis
2.1.1: MD 0.9 g/dL, 95% CI 0.38 to 1.42; Attallah 2006); (
Analysis 2.1.2: MD 1.9 g/dL, 95% CI 1.64 to 2.16; Ayli 2004).
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Haematocrit
Attallah 2006 did not report data on participants’ haematocrit lev-
els. Ayli 2004 reported that among interventional armparticipants
haematocrit was significantly higher than those in the control arm
(Analysis 2.2: MD 6.8%, 95% CI 5.67 to 7.93).
Transferin saturation (TSAT)
Attallah 2006 reported that TSAT was significantly higher in in-
terventional than control arm participants (Analysis 2.3.1: MD
8.00%, 95% CI 6.22 to 9.78). There was no significant differ-
ence in TSAT between study arms reported by Ayli 2004 (Analysis
2.3.2: MD 1.30%, 95% CI -3.99 to 6.59).
Ferritin
Attallah 2006 reported that ferritinwas significantly higher among
interventional than control arm participants (Analysis 2.4.1: MD
8.00 ng/mL, 95% CI -85.51 to 101.51). There was no significant
difference between study arms reported by Ayli 2004 (Analysis
2.4.2: MD -3.00 ng/mL, 95% CI -43.46 to 37.46).
Haemoglobin content in reticulocytes (CHr)
Attallah 2006 reported that CHr was significantly higher in inter-
ventional than control arm participants (Analysis 2.5: MD 0.90
pg, 95% CI 0.40 to 1.40). Ayli 2004 did not report CHr data.
Inflammatory biomarkers: C-reactive protein
Attallah 2006 reported C-reactive protein was significantly lower
in vitamin C group compared to the control group (Analysis
2.6.1: MD -1.20 mg/dL, 95% CI -1.69 to -0.71). There was no
significant difference between study arms in C-reactive protein
reported by Ayli 2004 (Analysis 2.6.2: MD -0.4 mg/dL, 95% CI
-3.0 to 2.2).
Markers of oxidative stress
NeitherAttallah 2006 nor Ayli 2004 reportedmarkers of oxidative
stress.
ESA and intravenous iron doses
ESA dose
Attallah 2006 reported ESA was significantly lower in vitamin c
group compared to the control group (Analysis 3.1: MD -18 U/
kg/wk, 95% CI -35.62 to -0.38). Ayli 2004 did not report data
on ESA dose.
Intravenous iron therapy dose
Attallah 2006 reported that there was no significant difference in
intravenous iron therapy dose between the study arms (Analysis
3.2: MD -0.20 mg/wk, 95% CI -16.15 to 15.75). Ayli 2004 did
not report on intravenous iron therapy dose.
Other outcomes
Hospitalisation days
Neither Attallah 2006 nor Ayli 2004 reported numbers of hospi-
talisation days.
Quality of life scores
NeitherAttallah 2006 nor Ayli 2004 reported quality of life scores.
D I S C U S S I O N
The results of this systematic review highlight the absence of ad-
equately powered randomised controlled trials (RCT) examining
the effect of various interventions to treat ESA hyporesponsive-
ness.We found that there was insufficient and inadequate evidence
to recommend any intervention to ameliorate ESA-hyporespon-
siveness.
We identified only one RCT that definedESA-hyporesponsiveness
as intravenous EPO dose ≥ 450 U/kg/wk (Attallah 2006). When
inclusion criteria were extended to include subcutaneous EPO
dose ≥ 200 U/kg/wk, another study, Ayli 2004, was found to be
eligible for inclusion.
In relation to intravenous vitamin C therapy, Attallah 2006
demonstrated increases in haemoglobin, haemoglobin content in
reticulocytes, and transferin saturation; and reductions in erythro-
poietin dose and C-reactive protein. Ayli 2004 reported that use of
high-flux dialyser for six months was associated with improvement
in haemoglobin, but there was no effect on C-reactive protein or
iron studies. Both Attallah 2006 and Ayli 2004 were single-centre
studies and included 42 and 48 participants respectively. The stud-
ies included only haemodialysis patients, and hence, results may
not be generalisable to CKD patients not yet on dialysis, those on
peritoneal dialysis, or in settings where patient populations differ.
There is no single widely accepted definition of ESA resistance.
KDOQI has defined ESA resistance as failure to achieve haemo-
globin 11 g/dL with ESA dose equivalent to epoetin greater than
500 IU/kg/wk (KDOQI 2006). Publication of KDIGO anaemia
guidelines is expected this year. As yet, there have been no RCTs
performed explicitly in patients with ESA resistance as defined by
KDOQI.
7Interventions for erythropoietin-resistant anaemia in dialysis patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In theNormalHaematocrit Cardiac Trial, more participants in the
normal haematocrit group reached the primary endpoint (com-
posite of death and non-fatal myocardial infarction) with mean
erythropoietin doses of 440 IU/kg/wk, which is lower than the
KDOQI definition (Besarab 1998). In the CHOIR trial, it was
reported that ESA dose > 20,000 IU/wk was associated with in-
creased risk of death, congestive heart failure, stroke, and myocar-
dial infarction (Szczech 2008).
Several observational studies have suggested a linear association be-
tween ESA dose and adverse outcomes (Brookhart 2010; Messana
2009; Regidor 2006; Zhang 2004; Zhang 2009). There is substan-
tial variability in the reporting of ESA dose, such as IU/kg/wk, IU/
wk, or ESA dose normalised to haemoglobin level. Therefore, the
current KDOQI definition of ESA resistance needs to be revised,
and the new definition should be based on ESA-resistance index
(ERI) rather than ESA dose to bring uniformity in reporting.
The revised inclusion criteria of the ongoing HERO Study are
ESA-resistance index ≥ 1.0 IU/kg/wk/haemoglobin for epoetin-
treated patients and ≥ 0.005 µg/kg/wk/g haemoglobin for darbe-
poetin-treated patients (Johnson 2008). Table 1 presents current
definitions of ESA resistance.
An emerging body of evidence indicates more harm than bene-
fit from targeting higher haemoglobin levels with ESA therapy.
Patients who needed higher doses of ESA experienced increased
mortality at any haemoglobin level, and patients who achieved
target haemoglobin levels had better outcomes than those who did
not.
Further RCTs are needed urgently to consider the clinical impacts
of therapies purported to reduce ESA resistance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on two small, single-centre studies, there was inadequate
evidence to recommend any intervention to ameliorate ESA-hy-
poresponsiveness.
Implications for research
Adequately powered multicentre RCTs involving a wide range
of CKD patients receiving ESA therapy should be conducted as
a priority. In addition to those on haemodialysis, future RCTs
should include pre-dialysis CKD patients as well people receiving
peritoneal dialysis.
Future studies should focus on true ESA responsiveness rather
than a haemoglobin-targeted approach. Importantly, these studies
should also include cost-effectiveness and economic analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Attallah 2006
Methods • Study design: RCT
• Time frame: NS
• Follow-up period: 6 months
Participants • Country: USA
• Setting: large inner-city HD centre
• Inclusion criteria: ESKD patients receiving HD therapy for at least 6 months;
administered IV EPO ≥ 6 months at dose ≥ 450 U/kg/wk; 3 month average Hb level
≤ 11 g/dL; ferritin level > 500 ng/mL; TSAT ≤ 50% and administered maintenance
IV iron
• Number (treatment/control): 20/22
• Age (mean ± SD) years: treatment group (50.6 ± 4.7); control group (49.0 ± 5.9)
• Sex (M/F): treatment group (9/11); control group (10/12)
• Exclusion criteria: bone marrow malignancy; myelodysplastic syndrome; chronic
infection; haemochromatosis; haemoglobinopathies; significant bleeding (decrease in
Hb > 2 g/L) during the past 3 months; mean corpuscular volume > 100 fL; CRP > 20
mg/dL; Bio-PTH > 500 pg/mL (ng/L); aluminium level > 20 µg/L
Interventions Treatment group
• Vitamin C
◦ Dose: 300 mg IV on each dialysis session
Control group
• No treatment






Notes • Patients were to be withdrawn from the study if they developed bone marrow
malignancy, myelodysplastic syndrome, haemochromatosis, or blood loss of ≥ 500 mL
during the 6 month study period
• Patients on peritoneal dialysis were excluded from the study.
• One patient from the control arm was excluded because of significant upper
gastrointestinal bleeding
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed with blocks
of 4
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Attallah 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Stated “concealed randomisation was per-
formed using 1:1 allocation ratio with
blocks of 4”. No further information pro-
vided








Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed up or accounted
for at 6 months
Selective reporting (reporting bias) Unclear risk Hb changes in individual patient data are
presented infigures only. Itwas unclear how
many patients in each arm achieved target
Hb
Other bias High risk Single-centre study
Ayli 2004
Methods • Study design: RCT
• Time frame: NS
• Follow-up period: 6 months
Participants • Country: Turkey
• Setting: single centre
• Inclusion criteria: ESKD patients receiving HD; administered SC EPO ≥ 6
months at ≥ 200 U/kg/wk; Hb level ≤ 11 g/dL
• Number (treatment/control): 24/24
• Age (mean ± SD) years: treatment group (59.9 ± 14.9); control group (58.3 ± 13.
1)
• Sex (M/F): treatment group (12/12); control group (14/10)
• Exclusion criteria: iron deficiency; chronic blood loss; acute or chronic infection;
malnutrition; haemolysis; vitamin B12 or folic acid deficiency; haemoglobinopathies;
malignancy; treatment with ACEi or ARB
Interventions Treatment group
• Polysulphone high-flux dialyser (Fresenius F60)
Control group
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Ayli 2004 (Continued)
• Polysulphone low-flux dialyser (Fresenius F6 HPS)





• Vitamin B12 and folic acid levels
• Dialysis adequacy tests (urea reduction ratio and Kt/V urea)
• Beta 2 microglobulin
Notes • Patients on peritoneal dialysis were excluded from the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
Participants
Unclear risk Not described
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Not described
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed up or accounted
for at 6 months
Selective reporting (reporting bias) Unclear risk Proportion of participants in each arm
achieving target haemoglobin is not de-
scribed.Data onmeanEPOdose presented
in figure only
Other bias High risk Single-centre study, patients on peritoneal
dialysis were excluded
ACEi - angiotensin-converting enzyme inhibitor; ARB - angiotensin-II receptor blocker; CRP - C-reactive protein; DPO - darbepoetin;
EPO - erythropoietin; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; Hb - haemoglobin; HCT - haematocrit;
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HD - haemodialysis; IV - intravenous; NS - not stated; PTH - parathyroid hormone; RCT - randomised controlled trial; SC -
subcutaneous; TSAT - transferin saturation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abe 2010 Study participants did not have ESA resistance.
Acchiardo 1989 Study participants did not have ESA resistance.
Aliev 1997 Study participants did not have ESA resistance.
Andrulli 2010 Study participants did not have ESA resistance.
Ballal 1991 Study participants did not have ESA resistance.
Barany 1998 Study participants did not have ESA resistance.
Berns 1992 Study participants did not have ESA resistance.
Brockenbrough 2006 Study participants did not have ESA resistance.
Buchwald 1977 ESA was not used.
Cao 2010 Study participants did not have ESA resistance.
Caruso 1998 Study participants did not have ESA resistance.
Cerulli 2000 Study participants did not have ESA resistance.
Chan 2005 Study participants did not have ESA resistance.
Chen 2003 Study participants did not have ESA resistance.
Cruz 2008 Not RCT
Culleton 2007 Study participants did not have ESA resistance.
Deira 2003 Study participants did not have ESA resistance.
Di Iorio 2003 Study participants did not have ESA resistance.
ECAP Study 2006 Ineligible patient population
Eiselt 2000 Study participants did not have ESA resistance.
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(Continued)
Garcia Cortes 1999 Study participants did not have ESA resistance.
Garrote 2009 Ineligible patient population (this study included iron deficient patients who lacked true ESA resistance)
Gastaldello 1995 Not RCT
Gaughan 1997 Study participants did not have ESA resistance.
Giancaspro 2000 Ineligible patient population (this study included iron deficient patients who lacked true ESA resistance)
Hakemi 2005 Study participants did not have ESA resistance.
Hsu 2004 Study participants did not have ESA resistance.
Hung 2005 Study participants did not have ESA resistance.
Imada 2001 Study participants did not have ESA resistance.
ISRCTN96315193 Study participants did not have ESA resistance.
Jacobs 2006 Not RCT
Janssen 1995 Study participants did not have ESA resistance.
Kato 2000 Study participants did not have ESA resistance.
Keven 2003 Study participants did not have ESA resistance.
Klarenbach 2002 Not RCT
Kletzmayr 1999 Study participants did not have ESA resistance.
Koronis 2000 Study participants did not have ESA resistance.
Labonia 1995 Study participants did not have ESA resistance.
Lee 2001 Study participants did not have ESA resistance.
Locatelli 1999 Study participants did not have ESA resistance.
Locatelli 2000 Study participants did not have ESA resistance.
Malegos 2000 Study participants did not have ESA resistance.
Miyahara 1990 Study participants did not have ESA resistance.
Mydlík 2003 Not RCT
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(Continued)
Nakamoto 2008 Study participants did not have ESA resistance.
Navarro 2002 ESA not used in the control arm (compared erythropoietin to androgens)
Odabas 2003 Study participants did not have ESA resistance.
Ono 1992 Study participants did not have ESA resistance.
Onoyama 1989 Study participants did not have ESA resistance.
Opatrnì 1998 Study participants did not have ESA resistance.
Panichi 2011 Study participants did not have ESA resistance.
Rao 2003 Not RCT
Richardson 2003 Study participants did not have ESA resistance.
Saxena 1997 Study participants did not have ESA resistance.
Sezer 2002 Study participants did not have ESA resistance.
Shahrbanoo 2008 Study participants did not have ESA resistance.
Sheashaa 2005 Study participants did not have ESA resistance.
Sorge-Haedicke 2001 Study participants did not have ESA resistance.
Taji 2004 Study participants did not have ESA resistance.
Tarng 1998 Study participants did not have ESA resistance.
Tarng 1999 Study participants did not have ESA resistance.
Tarng 2004 Study participants did not have ESA resistance.
Ursea 1995 Study participants did not have ESA resistance.
Usberti 2002a Study participants did not have ESA resistance.
Usberti 2002b Study participants did not have ESA resistance.
Vaslaki 2006 Study participants did not have ESA resistance.
Wang 2000 Study participants did not have ESA resistance.
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Yang 2006 Study participants did not have ESA resistance.
ESA - Erythropoiesis-simulating agents; RCT - randomised control trial
Characteristics of ongoing studies [ordered by study ID]
Johnson 2008
Trial name or title The Hemoglobin elevation in Erythropoietin Resistance with Oxpentifylline (HERO Study)
Methods Investigator-initiated, prospective, double-blind, randomised, placebo-controlled phase 3 trial
Participants Inclusion criteria
• Adults aged ≥18 years with CKD stage 4 or 5 (on dialysis or eGFR < 30 mL/min/1.73 m²) able to give
informed consent and who have Hb concentration < 110 g/L for at least 3 months in spite of EPO dose ≥
200 IU/kg/wk or DPO dose ≥ 1 µg/kg/wk for at least 1 month. Revised criteria based on ESA-resistance
index ≥ 1.0 IU/kg/wk/g Hb for epoetin-treated patients and ≥ 0.005 µg/kg/wk/g Hb for DPO-treated
patients.
Exclusion criteria
• Patients with a history of psychological illness or condition which interferes with their ability to
understand or comply with the requirements of the study
• Pregnancy or breastfeeding
• Known hypersensitivity to, or intolerance of, oxpentifylline or other methylxanthines, such as caffeine,
theophylline or theobromine
• Active peptic ulcer disease
• Absolute or functional iron deficiency (ferritin < 100 µg/L and/or TSAT < 20%)
• Vitamin B12 or folate deficiency
• PTH > 100 pmol/L
• Serum aluminium > 2 µmol/L
• Urea reduction ratio < 65% or single pool Kt/V < 1.0 (HD patients) or total weekly Kt/V < 1.7 (PD
patients)
• Presence of systemic haematological disease (including antibody-mediated pure red cell aplasia) or
known haemoglobinopathy
• Major surgery, infection, acute myocardial infarction or malignancy within the last 3 months
• Melatonin treatment, androgen therapy or blood transfusion within the previous month
• Vitamin C therapy > 100 mg/d or at a dose that has changed within the last 3 months
• Haemorrhagic stroke or severe haemorrhage within the last 3 months.
Interventions Intervention arm
• Oxpentifylline 400 mg once daily
Control arm
• Identical placebo 1 tablet once daily
Outcomes Primary: difference in Hb concentration between the oxpentifylline and control groups at the end of the 4
month study period
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Johnson 2008 (Continued)
Starting date April 2008
Contact information ProfessorDavid Johnson, Level 2ARTSBuilding, Princess AlexandraHospital,Woolloongabba 4102Queens-
land, Australia Tel: 61-7-31765080, Fax: 61-7-31765480, Email: David Johnson@health.qld.gov.au
Notes
NCT01526798




• ESKD treated with chronic HD for at least 3 months
• Treatment with high-flux dialyzers for at least 3 months
• Age ≥18 years
• Receiving ESA to treat anaemia for at least 3 months
• Impaired ESA responsiveness as indicated by EPO resistance index > median of patients in study centre
• TSAT ≥ 20% (last routine value prior to randomisation)
• Serum ferritin ≥ 100 ng/mL (last routine value prior to randomisation)
Exclusion criteria
• Acute infection ≤ 4 weeks prior to randomisation
• HIV or hepatitis infection
• Catheter
• Chronic liver disease
• Active cancer
• Known blood dyscrasia (paraprotein abnormalities)
• Known bleeding disorders
• Bleeding episode ≤ 12 weeks prior to randomisation
• Blood/red cell transfusion ≤ 12 weeks prior to randomisation
• Hypoalbuminaemia defined as serum albumin concentration below 35 g/L (last routine value prior to
randomisation)
• Participation in another clinical interventional investigation
• Pregnancy
• Inability to give informed consent
• Planned transplantation within study period + 3 months
• Planned interventions requiring hospitalisation >1 week
Interventions Intervention arm: Device: Theralite (high cut-off HD), HD with Theralite dialyzer alternating with standard
high-flux dialyzer (Polyflux H)
Control arm: Device: Polyflux H, Conventional high-flux dialyzer
Outcomes EPO resistance index
Starting date March 2012
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NCT01526798 (Continued)
Contact information Dr. Ugo Teatini, Azienda Ospedaliera Garbagnate Milanese Ospedale Bollate - Divisione Nefrologia e Dialisi,
Bollate, Milan, Italy, 20021
Notes
CKD - chronic kidney disease; DPO - darbepoetin; EPO - erythropoietin; eGFR - estimated glomerular filtration rate; ESA - erythro-
poiesis-stimulating agent; Hb - haemoglobin; HD - haemodialysis; PD - peritoneal dialysis; PTH - parathyroid hormone; RCT -
randomised controlled trial; TSAT - transferrin saturation
24Interventions for erythropoietin-resistant anaemia in dialysis patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Clinical outcomes




participants Statistical method Effect size
1 Non-fatal cardiovascular events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Hospitalisations 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Haematology and biochemistry results




participants Statistical method Effect size
1 Haemoglobin 2 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Vitamin C versus control 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 High-flux versus low-flux
dialyser
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Haematocrit 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Transferin saturation (TSAT) 2 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Vitamin C versus control 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 High-flux versus low-flux
dialyser
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Ferritin 2 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Vitamin C versus control 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 High-flux versus low-flux
dialyser
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Haemoglobin content in
reticulocytes (CHr)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 C-reactive protein 2 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 Vitamin C versus control 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 High-flux versus low-flux
dialyser
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. ESA and IV iron doses




participants Statistical method Effect size
1 EPO dose 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 IV Iron 1 Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Clinical outcomes, Outcome 1 Non-fatal cardiovascular events.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 1 Clinical outcomes
Outcome: 1 Non-fatal cardiovascular events








Attallah 2006 3/20 4/21 0.79 [ 0.20, 3.09 ]
0.1 0.2 0.5 1 2 5 10
Favours vitamin C Favours control
Analysis 1.2. Comparison 1 Clinical outcomes, Outcome 2 Hospitalisations.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 1 Clinical outcomes
Outcome: 2 Hospitalisations








Attallah 2006 11/20 12/21 0.96 [ 0.56, 1.66 ]
0.5 0.7 1 1.5 2
Favours Vitamin C Favours control
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Analysis 2.1. Comparison 2 Haematology and biochemistry results, Outcome 1 Haemoglobin.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 1 Haemoglobin





N Mean(SD)[g/dL] N Mean(SD)[g/dL] IV,Random,95% CI IV,Random,95% CI
1 Vitamin C versus control
Attallah 2006 20 10.5 (0.9) 21 9.6 (0.8) 0.90 [ 0.38, 1.42 ]
2 High-flux versus low-flux dialyser
Ayli 2004 24 11.4 (0.5) 24 9.5 (0.4) 1.90 [ 1.64, 2.16 ]
-4 -2 0 2 4
Favours control Favours treatment
Analysis 2.2. Comparison 2 Haematology and biochemistry results, Outcome 2 Haematocrit.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 2 Haematocrit





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Ayli 2004 24 35.8 (2.1) 24 29 (1.9) 6.80 [ 5.67, 7.93 ]
-10 -5 0 5 10
Favours low-flux Favours high-flux
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Analysis 2.3. Comparison 2 Haematology and biochemistry results, Outcome 3 Transferin saturation
(TSAT).
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 3 Transferin saturation (TSAT)





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Vitamin C versus control
Attallah 2006 20 37.3 (3) 21 29.3 (2.8) 8.00 [ 6.22, 9.78 ]
2 High-flux versus low-flux dialyser
Ayli 2004 24 35.8 (9.6) 24 34.5 (9.1) 1.30 [ -3.99, 6.59 ]
-10 -5 0 5 10
Favours control Favours treatment
Analysis 2.4. Comparison 2 Haematology and biochemistry results, Outcome 4 Ferritin.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 4 Ferritin





N Mean(SD)[ng/mL] N Mean(SD)[ng/mL] IV,Random,95% CI IV,Random,95% CI
1 Vitamin C versus control
Attallah 2006 20 732 (149) 21 724 (156.5) 8.00 [ -85.51, 101.51 ]
2 High-flux versus low-flux dialyser
Ayli 2004 24 267 (73) 24 270 (70) -3.00 [ -43.46, 37.46 ]
-200 -100 0 100 200
Favours control Favours treatment
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Analysis 2.5. Comparison 2 Haematology and biochemistry results, Outcome 5 Haemoglobin content in
reticulocytes (CHr).
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 5 Haemoglobin content in reticulocytes (CHr)





N Mean(SD)[pg] N Mean(SD)[pg] IV,Random,95% CI IV,Random,95% CI
Attallah 2006 20 30.7 (0.9) 21 29.8 (0.7) 0.90 [ 0.40, 1.40 ]
-10 -5 0 5 10
Favours control Favours vitamin C
Analysis 2.6. Comparison 2 Haematology and biochemistry results, Outcome 6 C-reactive protein.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 2 Haematology and biochemistry results
Outcome: 6 C-reactive protein





N Mean(SD)[mg/dL] N Mean(SD)[mg/dL] IV,Random,95% CI IV,Random,95% CI
1 Vitamin C versus control
Attallah 2006 20 0.9 (0.3) 21 2.1 (1.1) -1.20 [ -1.69, -0.71 ]
2 High-flux versus low-flux dialyser
Ayli 2004 24 6.3 (4.5) 24 6.7 (4.7) -0.40 [ -3.00, 2.20 ]
-4 -2 0 2 4
Favours treatment Favours control
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Analysis 3.1. Comparison 3 ESA and IV iron doses, Outcome 1 EPO dose.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 3 ESA and IV iron doses
Outcome: 1 EPO dose





N Mean(SD)[IU/kg/wk] N Mean(SD)[IU/kg/wk] IV,Random,95% CI IV,Random,95% CI
Attallah 2006 20 429 (24.7) 21 447 (32.5) -18.00 [ -35.62, -0.38 ]
-50 -25 0 25 50
Favours Vitamin C Favours control
Analysis 3.2. Comparison 3 ESA and IV iron doses, Outcome 2 IV Iron.
Review: Interventions for erythropoietin-resistant anaemia in dialysis patients
Comparison: 3 ESA and IV iron doses
Outcome: 2 IV Iron





N Mean(SD)[mg/wk] N Mean(SD)[mg/wk] IV,Random,95% CI IV,Random,95% CI
Attallah 2006 20 26.6 (25.4) 21 26.8 (26.7) -0.20 [ -16.15, 15.75 ]
-20 -10 0 10 20
Favours vitamin C Favours control
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A D D I T I O N A L T A B L E S
Table 1. Current definitions of ESA resistance
Author/study Definition of ESA resistance
KDOQI (KDOQI 2006) Epoetin dose > 500 IU/kg/wk
Normal Haematocrit Cardiac Trial (Besarab 1998) Epoetin dose 440 IU/kg/wk in the normal haematocrit group
CHOIR study (Szczech 2008) Epoetin dose > 20,000 IU/wk
Attallah 2006 Epoetin dose > 450 IU/kg/wk (IV)
Ayli 2004 Epoetin dose > 200 IU/kg/wk (SC)
Johnson 2008; HERO Study Epoetin dose ≥ 200 IU/kg/wk or darbepoetin dose ≥ 1 µg/kg/wk
HERO Study (revised criteria) ESA-resistance index (ERI) ≥ 1.0 IU/kg/wk/g Hb for epoetin-treated patients
and ≥ 0.005 µg/kg/wk/g Hb for darbepoetin-treated patients
Hb - haemoglobin
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. dialysis:ti,ab,kw
2. (hemodia* or haemodia*):ti,ab,kw
3. (hemofiltration or haemofiltration):ti,ab,kw
4. (#1 OR #2 OR #3)
5. an*emia:ti,ab,kw
6. “iron overload”:ti,ab,kw
7. (#5 OR #6)
8. erythropo*etin:ti,ab,kw
9. (erythropo*esis next stimulating next agent*):ti,ab,kw





31Interventions for erythropoietin-resistant anaemia in dialysis patients (Review)









22. (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20
OR #21)
23. (#4 AND #7 AND #22)
MEDLINE 1. exp Renal Dialysis/
2. dialysis.tw.
3. (hemodialysis or haemodialysis).tw.
4. (hemofiltration or haemofiltration).tw.





10. (an?emia or an?emic).tw.
11. or/7-10
12. exp Erythropoietin/























8. erythropo?esis stimulating agent$.tw.
9. erythropo?etin.tw.
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23. exp Renal Replacement Therapy/
24. dialysis.tw.
25. (hemodialysis or haemodialysis).tw.
26. (hemofiltration or haemofiltration).tw.
27. (hemodiafiltration or haemodiafiltration).tw.
28. or/23-27
29. and/5, 22, 28
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias:Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
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(Continued)
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
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(Continued)
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias:Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
35Interventions for erythropoietin-resistant anaemia in dialysis patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol for this review, we had planned that one of our inclusion criteria would define ESA resistance. Evidence of ESA-
resistance, defined as failure to achieve or maintain target range haemoglobin/haematocrit levels in spite of appropriate doses of the ESA
(erythropoietin dose ≥ 450 U/kg/wk intravenous administration or ≥ 300 U/kg/wk for subcutaneous administration or darbepoetin
dosage ≥ 1.5 µg/kg/wk) (KDOQI 2001; Locatelli 2004) was to be applied. This inclusion criterion was amended because only one
eligible study was found.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Renal Dialysis; Anemia [blood; ∗drug therapy]; Drug Resistance; Erythropoiesis [∗drug effects]; Erythropoietin [∗administration &
dosage]; Hematocrit; Kidney Failure, Chronic [∗complications; therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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